Table 1.
Characteristics
| Characteristics | Overall Population (N = 17) | Without Pneumonitis (N = 12) | With Pneumonitis (N = 5) | p Value |
|---|---|---|---|---|
| Backgrounds | ||||
| Median age | 70.0 (66.0–73.0) | 69.0 (65.5–73.5) | 70.0 (68.0–73.0) | 0.634 |
| Sex | 1.000 | |||
| Male | 16 (94.1) | 11 (91.7) | 5 (100) | |
| Female | 1 (5.9) | 1 (8.3) | 0 | |
| Smoking history | — | |||
| Current | 3 (17.6) | 2 (16.7) | 1 (20.0) | |
| Past | 14 (82.4) | 10 (83.3) | 4 (80.0) | |
| Never | 0 | 0 | 0 | |
| Height (cm) | 167 (164–170) | 167 (165–170) | 164 (163–168) | 0.506 |
| Body weight (kg) | 66.1 (58.4–74.0) | 69.8 (65.9– 76.3) | 58.4 (56.2– 62.1) | 0.049 |
| Performance status (0/1) | 1.000 | |||
| 0 | 4 (23.5) | 3 (25.0) | 1 (20.0) | |
| 1 | 13 (76.5) | 9 (75.0) | 4 (80.0) | |
| SpO2 (%) | 96.0 (95.0–98.0) | 97.0 (95.8–98.0) | 96.0 (95.0– 96.0) | 0.422 |
| Lung cancer | ||||
| Histologic type | — | |||
| Adenocarcinoma | 9 (52.9) | 6 (50.0) | 3 (60.0) | |
| Squamous cell carcinoma | 7 (41.2) | 5 () | 2 (40.0) | |
| Not otherwise specified | 1 (5.9) | 1 (8.3) | 0 | |
| Staging | — | |||
| IIIA | 2 (11.8) | 2 (16.7) | 0 | |
| IIIB | 4 (23.5) | 3 (25.0) | 1 (20.0) | |
| IIIC | 2 (11.8) | 1 (8.3) | 1 (20.0) | |
| IVA | 3 (17.6) | 2 (16.7) | 1 (20.0) | |
| IVB | 3 (17.6) | 1 (8.3) | 2 (40.0) | |
| Recurrence | 3 (17.6) | 3 (25.0) | 0 | |
| PD-L1 expressiona [TPS (%)] | — | |||
| <1 | 4 (23.5) | 3 (25.0) | 1 (20.0) | |
| 1–49 | 3 (17.6) | 1 (8.3) | 2 (40.0) | |
| ≥50 | 7 (41.2) | 6 (50.0) | 1 (20.0) | |
| Unknown | 3 (17.6) | 2 (16.7) | 1 (20.0) | |
| No. of previous lines of therapies | — | |||
| 1 | 11 (64.7) | 6 (50.0) | 5 (100) | |
| 2 | 3 (17.6) | 3 (25.0) | 0 | |
| 3 | 2 (11.8) | 2 (16.7) | 0 | |
| 4 | 1 (5.9) | 1 (8.3) | 0 | |
| IP | ||||
| Radiologic pattern | — | |||
| UIP | 6 (35.3) | 3 (25.0) | 3 (60.0) | |
| Probable UIP | 3 (17.6) | 3 (25.0) | 0 | |
| Indeterminate for UIP | 8 (47.1) | 6 (50.0) | 2 (40.0) | |
| Honeycomb lung on HRCT | 7 (41.2) | 3 (25.0) | 4 (80.0) | 0.101 |
| %FVC (%) | 85.4 (80.6– 92.2) | 84.9 (80.2– 92.2) | 86.4 (84.0– 92.2) | 0.721 |
| %DLco (%) | 54.4 (48.2–65.2) | 57.0 (51.3–66.3) | 52.1 (47.8–63.3) | 0.646 |
Note: Categorical data are presented as numbers (percentages) and compared using the Fisher’s exact test. Continuous data are presented as medians (interquartile ranges) and compared using Mann-Whitney U test. The p value was calculated by comparing subjects with and without pneumonitis; p less than 0.05 was statistically significant.
%DLco, % diffusing capacity for carbon monoxide; %FVC, % forced vital capacity; IP, interstitial pneumonia; PD-L1, programmed cell death-ligand 1; SpO2, saturation of peripheral oxygen; TPS, tumor proportion score; UIP, usual IP; HRCT, high-resolution computed tomography.
a
PD-L1 expression was assessed by immunohistochemistry using 22C3 pharmDx assay (Agilent Technologies, Santa Clara, CA).